Results 1 to 10 of about 86,457 (338)

Loss of p21 does not protect against premature ovarian insufficiency caused by alkylating agents [PDF]

Frontiers in Endocrinology
BackgroundRecent studies have focused on investigating the role of cellular senescence in ovarian aging. Targeting cellular senescence has been proposed as a potential strategy to improve ovarian aging.
Xiaohui Lu, Yongli Han, Jiaming Song, Qin Wan, Pengfei Liu, Li Chen, Yufeng Wang, Pingping Xue, Xiuliang Dai   +8 more
doaj   +2 more sources

Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents [PDF]

Neoplasia: An International Journal for Oncology Research
The ADP-ribosyl hydrolases PARG and ARH3 counteract PARP enzymatic activity by removing ADP-ribosylation. PARG and ARH3 activities have a synthetic lethal effect; however, the specific molecular mechanisms underlying this response remain unknown.
Rocco Caggiano, Evgeniia Prokhorova, Lena Duma, Kira Schützenhofer, Raffaella Lauro, Giuliana Catara, Rosa Marina Melillo, Angela Celetti, Rebecca Smith, S John Weroha, Scott H Kaufmann, Ivan Ahel, Luca Palazzo   +12 more
doaj   +2 more sources

In Situ Evaluation of the GSH Depletion Ability of Various Alkylating Agents and the Protective Effect of Several Active Thiol Compounds Based on High-Content Cell Analysis [PDF]

Toxics
The depletion degree of reduced glutathione is a critical indicator for assessing the toxicity of alkylating agents. In the present research, we have developed a novel method to evaluate the glutathione (GSH) depletion induced by a series of alkylating ...
Jing Guo, Zhi Li, Jiao Wang, Bo Ma, Liang Zhang, Hairui Wang, Jianfeng Wu, Jianwei Xie   +7 more
doaj   +2 more sources

Non‐alkylating agents‐induced gonadotoxicity in pre‐pubertal males: Insights on the clinical and pre‐clinical front [PDF]

Clinical and Translational Science
Whilst chemotherapy regimens have proven to be more successful for pediatric cancer patients over the years, their influence on long‐term side effects is relatively poorly understood.
Sruthi Sriram, Tiago Macedo, Annelies Mavinkurve‐Groothuis, Marianne van deWetering, Leendert H. J. Looijenga   +4 more
doaj   +2 more sources

Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer [PDF]

Frontiers in Oncology, 2022
Exposure to alkylating agents and radiation may cause damage and apoptosis in cancer cells. Meanwhile, this exposure involves resistance and leads to metabolic reprogramming to benefit cancer cells.
Yu-Chan Chang, Peter Mu-Hsin Chang, Peter Mu-Hsin Chang, Peter Mu-Hsin Chang, Chien-Hsiu Li, Ming-Hsien Chan, Yi-Jang Lee, Ming-Huang Chen, Ming-Huang Chen, Michael Hsiao, Michael Hsiao   +10 more
doaj   +2 more sources

Novel Pathways of Oxidative and Nitrosative Inactivation of the Human MGMT Protein in Colon Cancer and Glioblastoma Cells: Increased Efficacy of Alkylating Agents In Vitro and In Vivo [PDF]

Diseases
Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a unique antimutagenic DNA repair protein that plays a crucial role in conferring resistance to various alkylating agents in brain tumor therapy.
Debasish Basak, Agm Mostofa, Hanumantha Rao Madala, Kalkunte S. Srivenugopal   +3 more
doaj   +2 more sources

Balancing repair and tolerance of DNA damage caused by alkylating agents [PDF]

, 2012
Alkylating agents constitute a major class of frontline chemotherapeutic drugs that inflict cytotoxic DNA damage as their main mode of action, in addition to collateral mutagenic damage.
A Al-Attar, A Bapat, A Schambach, A Shibata, A Simeonov, AE Kiltie, AE Pegg, AH Trainer, AJ Deans, AS Jaiswal, AS Jaiswal, B Kaina, B Kaina, B Kaina, B Kaina, B Rydberg, B Sedgwick, BA Kunz, BJ Glassner, BJ Glassner, BP Engelward, BP Engelward, BP Engelward, C Fleischmann, CD Curtis, CD Mol, CE Ström, D Ravi, D Starcevic, D Svilar, D Wang, D Wilson, DC Cabelof, DR Duckett, Dragony Fu, DW Kufe, E Allay, E Allay, E Batts, E Jelezcova, F Calleja, F Drablos, F Mégnin-Chanet, GC Stachelek, GE Kisby, H Bartsch, H Farmer, H Interthal, H Kawate, HE Bryant, HY Hu, I Casorelli, I Kaasen, I Rusyn, J Dosch, J Jelinek, J Jiang, J Klapacz, J Klapacz, J Lips, J Paik, J Weingart, J-b Tang, JA Allay, JA Quinn, JB Sweasy, JC Huang, Jennifer A. Calvo, JH Robbins, JK Horton, JK Horton, JM Bugni, JM de Murcia, JS Reese, JS Reese, JS Reese, JT Hamilton, JW Cardinal, JY Choi, K Ballschmiter, K Becker, K Becker, K Becker, K Chan, K Ochs, K Sakumi, K Savitsky, K Takenaka, K-i Yoshioka, KH Almeida, KH Lauritzen, L Gate, L Haracska, L Haracska, L Haracska, L Liu, L Liu, L Liu, L Liu, L Mirabello, L Samson, L Wang, L Weissman, L Weissman, L Zecca, LA Loeb, LB Meira, LB Meira, Leona D. Samson, LJ Hofseth, LJ Rasmussen, LJ Reha-Krantz, LJ Stallons, LL Dumenco, LM Posnick, M Briegert, M Christmann, M Christmann, M Eich, M Hewish, M Jansen, M Koi, M Luo, M Rinne, M Rouleau, MA Lovell, ME Arana, ME Hegi, ME Moynahan, MJ Hickman, MJ Hickman, ML Fishel, ML Hegde, ML Rinne, MR Kelley, MS Bobola, MZ Zdzienicka, N Burns, N de Wind, N Mojas, N Shrivastav, N Valeri, NA Yamada, NH Zaidi, NJ Toft, NK Kim, OJ Sansom, OJ Sansom, OJ Sansom, OK Mirzoeva, OM Sieber, P Branch, P Cejka, P Hanawalt, P Monti, P Monti, P Moskwa, P Rajesh, P Taverna, P Taverna, PJ McKinnon, R Maze, R Maze, R Prasad, R Tsaryk, RB Roth, RC Fry, RE Johnson, RH Elder, RJ Hansen, RN Trivedi, RW Sobol, RW Sobol, RW Sobol, RW Sobol, S Freitas, S Hongeng, S Kakolyris, S Ragg, S Wilson, S Wirtz, SE Andrew, SF El-Khamisy, SR Cerda, SS Hecht, SS Lange, T Coquerelle, T Iida, T Iwakuma, T Izumi, T Moritz, T Neff, T Neff, T Tsuzuki, TF Gajewski, TJ Begley, TS Fenske, V Di Maso, V Poltoratsky, W Lutz, W Meikrantz, W Xiao, WP Roos, WP Roos, X Qin, X Qin, Y Jiang, Y Jiang, Y Kee, Y Lee, Y Nakatsuru, ZQ Zhou   +211 more
core   +3 more sources

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy [PDF]

Biomedicines, 2019
The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor.
Hannah Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D. Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff   +7 more
doaj   +2 more sources

Polyphenols enhance the activity of alkylating agents in leukaemia cell lines [PDF]

Oncotarget, 2019
Polyphenols have been shown to sensitize solid tumours to alkylating agents such as cisplatin, and induce apoptosis and/or cell-cycle arrest. Here, we assess the effects of five polyphenols alone and in combination with three alkylating agents: cisplatin,
Blagosklonny, Büsselberg, Chandra, Cidlowski, Dashwood, Day, Domenicotti, Estrela, Huang, Huang, Hung, Huq, Jiao, Johnston, Jordan-Mahy, Jordan-Mahy, Jordan-Mahy, Jordan-Mahy, Kay, Khoo, Kofler, Kwoh, Lee, Liang, Lou, McCabe, Mumper, Ong, Pokharel, Pommier, Rauko, Reisman, Schiffer, Sharma, Siddik, Siddik, Singh, Singh, Trojaborg, Tsao, Wang, Wang, Wasserman, Weng, Yanikkaya-Demirel, Zabel   +45 more
core   +2 more sources

Beyond Alkylating Agents for Gliomas: Quo Vadimus? [PDF]

Am Soc Clin Oncol Educ Book, 2017
Vinay K. Puduvalli, Rekha Chaudhary, Samuel G. McClugage, James M. Markert   +3 more
openalex   +3 more sources